| Name | JNJ-67856633 |
| Description | JNJ-67856633 is an orally active, first-in-class, potent, selective and allosteric inhibitor of MALT1 protease . JNJ-67856633 lead to tumor stasis in some cases. |
| In vitro | JNJ-67856633 is effective and highly bioavailable in both mouse and rat tumors, and in some cases led to tumor stasis. JNJ-67856633 results in potent in vivo pharmacodynamic shutdown in CD79b- as well as CARD11-mutant ABC-DLBCL models as measured by serum IL10 or uncleaved BCL10 levels in tumors[1][3]. |
| In vivo | Treatment with JNJ-67856633 was observed to cause dose-dependent inhibition of Tregs (CD4+CD25+FoxP3+) generation following CD3/28 stimulation, suggesting a potential immune-modulatory role of MALT1 inhibition[3]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 125 mg/mL (267.48 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 5 mg/mL (10.7 mM), Sonication is recommended.
|
| Keywords | selective | potent | orally | mucosa associated lymphoid tissue lymphoma translocation gene 1 | MALT1 | JNJ-67856633 | JNJ67856633 | JNJ 67856633 | Inhibitor | inhibit | allosteric | active |
| Inhibitors Related | MALT1-IN-9 | Val-Arg-Pro-DL-Arg-Fluoromethylketone | MALT1-IN-14 | RGT-068A | Mepazine acetate | MLT-748 | Mepazine hydrochloride | MLT-943 | Mepazine | (S)-MALT1-IN-5 | Z-VRPR-FMK | MALT1 inhibitor MI-2 |
| Related Compound Libraries | Bioactive Compound Library | Hematonosis Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |